Sana Biotechnology, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.42 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.46, a 35.91% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $1.81, a 71.98% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $6.46, a 160.48% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $2.48, a 35.25% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.96, a 66.32% decline from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $5.82, a 122.14% increase from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.62, a 33.16% decline from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $3.92, a 72.43% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.42 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $2.46 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $1.96 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $1.79 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.79 10-Q · filed 2026-08-10 | |||
| 2025-03-31 | $1.81 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | $5.82 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $5.98 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $6.19 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $6.46 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | $2.62 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $2.62 10-Q · filed 2024-11-08 | |||
| 2023-06-30 | $2.60 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | $2.48 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $3.92 10-K · filed 2025-03-17 | |||
| 2022-09-30 | $3.96 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $3.83 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $3.83 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | $14.22 10-K · filed 2024-02-29 | |||
| 2021-09-30 | $14.64 10-Q · filed 2022-11-02 | |||
| 2021-06-30 | $15.30 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | $16.75 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $3.52 10-K · filed 2023-03-16 | |||
| 2020-09-30 | $0.54 10-Q · filed 2021-11-08 | |||
| 2020-06-30 | $1.21 10-Q · filed 2021-08-04 | |||
| 2020-03-31 | $1.08 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $0.92 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |